Business
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 11:15 a.m. ET in Coral Gables, FL. A live audio webcast of the fireside chat will be available
About this update from Prime Medicine, Inc.
[{"type":"image","alt":"Prime Medicine, Inc.","displaySize":"","headline":null,"caption":"Prime Medicine, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/7c5397d80babf7cd71ba3f6a787c0b3f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S_7U4Aj8CXur3GvYQq2zOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7c5397d80babf7cd71ba3f6a787c0b3f","width":300,"height":100}},"lazy":false},{"type":"text","content":"CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 11:15 a.m. ET in Coral Gables, FL.","length":439,"tagName":"p"},{"type":"text","content":"A live audio webcast of the fireside chat will be available under “Events & Presentations” in the News & Events section of the Company’s website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days following the event.","length":283,"tagName":"p"},{"type":"text","content":"About Prime Medicine","length":20,"tagName":"p"},{"type":"text","content":"Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.","length":744,"tagName":"p"},{"type":"text","content":"Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core...